. Our company provides different scorpion venom with the best
quality for Research, Drug Discovery & manufacturing.  if you are interested, we can work together. Our website is: www.shayganexport.com

Join expert panellists from Novartis, UCB, Shire and S3 Connected Health discussing how to bring the next generation of PSPs to us more quickly.

You can sign up for this free webinar here: http://bit.ly/nextgenpsp

Digital projects require continuous learning to create optimum value for your customers. Or put simply, they require some trial and error.

“A fail-fast culture is an experimental one. As long as we don’t just fail. Try your first approach, see if it works. Try a second approach and so on. Just keep trying,” said Panos Papakonstantinou, Head of Digital Commercial Europe, Novartis, at a recent eyeforpharma conference.

Gain insight into Novartis’ digital strategy and learn how to target real outcomes with a smarter digital strategy.
Discover more from eyeforpharma's expert line up of digital speakers at their Marketing & Customer Innovation Europe (London, 16-17th Oct)

You can download the brochure and complete agenda here: http://bit.ly/2vQjv4G

Medical has always been heavily associated with driving authenticity through scientific narratives and data, but when it comes to RWE, questions remain. How does medical step up and take its place as the steward of data? How can RWE and RCT wisdom be fused together to drive the right type of action from every stakeholder?

In eyeforpharma’s latest webinar, they’ll propose a new plan for Medical. Pfizer, Novartis and eyeforpharma will look at existing skills that have enabled success, and whether they will suffice in a future where medical has a clear mandate to deliver more from Real-World Evidence.

Sign up for free here: http://bit.ly/2Mucwbc

Their panel of experts include:

- Sonal Bhatia, Vice President, North America Medical Lead, Rare Disease, Pfizer
- Omar Dabbous, Vice President, Global Health Economics and Outcomes Research and Real-World Evidence, Novartis

And more to be announced…

Sign up for the free webinar on September 12th here: http://bit.ly/2Mucwbc

Don’t worry if you can’t make the live viewing, sign up anyway and you’ll still receive the recordings.

There’s never been a more exciting time to work in patient engagement. Patient centricity is the buzzword of the industry – but it’s up to us to ensure it becomes more than that, embedding patient value at the heart of pharma’s model.

To that end, eyeforpharma spoke to leaders from Sanofi, Ipsen, Gilead, Viiv Healthcare and others to discover what they see as the biggest opportunities in patient engagement today.

Read the full magazine here - http://bit.ly/PatientCentricityTrends


Covered in our magazine:
• The six ways pharma can use AI to positively impact patients
• How pharma can reduce the effects of stigma and enhance the patient experience
• The evolution of the Chief Patient Officer role in championing the patient voice internally

Download your copy for free here - http://bit.ly/PatientCentricityTrends

Anyone here from Japan? We are currently hiring professionals within Pharmaceutical and Medical Device industry.


Feel free to contact us if you are keen in learning more about the market and discovering other opportunities in Pharmaceutical or Medical Devices space.
Referral is very much welcome!

My name is Yanyao Yi, and I'm a PharmD/HIIM Certificate Candidate 2020 from Nashville, TN, USA. If anyone is near this area, I'd love to grab a coffee with you. Please let me know!

Like oil, data needs to be found and extracted, cleaned and refined, then transported to its destination.

Real-world evidence is seen by many as a key fuel to power pharma’s next evolution – from a drug developer/seller to an end-to-end healthcare solutions provider – but pharma still faces many challenges along the way.

In eyeforpharma’s latest Trends in Real-World Evidence Magazine, we feature articles that explore how to manage these challenges.

Download the latest free magazine here: https://bit.ly/2KR7jKF

Hear key insights from:

- Joseph Dye, Head of HEOR, Neurology US, UCB
- Sean McElligott, Director, Global Market Access Lead Dermatology, Janssen
- Michelle Hoiseth, Corporate VP, Parexel International
- Aaron Mitchell, Managing Principal and Global Lead for R&D Excellence Practice, ZS
- Merat Baghaformer, Director of Marketing, Digital Health & Patient Care, Merck
- Sajan Khosla, Head of Real World Evidence – Center of Excellence, AZ

Read the full free magazine here: https://bit.ly/2KR7jKF

Imagine.

Today, we can easily get hold of data.

Customer data, patient data, real world data, benchmarking data.

Indeed, data is our ‘goldmine’.

It’s the future of our industry, according to Vas Naramishan, as he recently relaunched Novartis as a ‘medicine and data science company’.

But when Cambridge Analytica became news, and GDPR went live, data suddenly became more than just a commodity. It’s now something precious. Something more difficult to obtain.

Most now say that the tables have turned, and there is an inexorable rise in our personal quest for data privacy: so much so that soon we will begin treating data not just as something private, but as personal property. Belonging to the individual. Not ours.

If data becomes personal property, will that be a blessing or a curse for pharma? And industry in general? It’s a fascinating and potentially hugely impactful situation and it must be debated.

That’s why eyeforpharma is launching a new webinar (June 27th ,2PM BST) in order to explore how we will need to operate going forward, as data becomes something we increasingly have to earn. Joining us are some of pharma’s finest minds in data and blockchain technology.

Sign up for free now: https://goo.gl/9UyK3e


If you can’t make it on the day, sign up anyway and they’ll send you a recording afterwards.

Pharma faces fast changes around value and real-world evidence. They must gain access to relevant data at the right time, fulfil payer’s needs, grow patient engagement, implement new approaches and technologies, whilst saving money.

eyeforpharma spoke with Teva, Otsuka, CSL Behring, and several more to hear how to manage these expectations whilst providing data at standards needed to prove value in the real world to secure access.
Read the full magazine here and see how to use the chaos as an opportunity: https://goo.gl/P7Ctkm

Key themes discussed:

• Embedding a culture of value in early development and how to engage scientists
• A win-win-win situation: Work with payers, regulators while always involving patients
• Boost your value story by identifying new and innovative end points that payers are interested in

Click here to download the magazine and learn how to embrace changes: https://goo.gl/P7Ctkm

The introduction of counterfeit pharmaceutical products into the legitimate supply chain has become a global threat over the past years. To respond to the challenge, SAP and Boehringer Ingelheim are co-innovating to established a blockchain-based system that ensures the unique identification and verification of individual medicine packages. Such a system will enable patients and healthcare professionals to easily perform product verification, while ensuring secure data management along the supply chain.

The minimum expectation of MSLs and sales reps are far higher: we need trust creators, data sources, inspiring educators, fonts of patient insight, entrepreneurial line-managers and customer experience generators – all within a single person!

How can one rep deliver so much? Customers expect more and are working with yet-higher expectations from patients…pharma need to catch up.

Which is why we’re excited to announce a free one hour webinar (23rd May, 2PM BST) with our expert panellists from Sunovian, Daiichi Sankyo, BMS, CSL Behring and Qstream to discuss: https://goo.gl/QLkfZT

• The key steps being taken by forward-thinking companies to move reps away from a transactional to value-creating engagement
• The benefits and delivery of data-driven insights into a rep’s capabilities
• How enablement and training programs for reps and MSLs are changing to realise patient centricity
• The new skills needed to gain true partnership with medical professionals

Click here to sign-up and find out how to support the development of pharma reps, lift the role of medical affairs and truly deliver a patient centric mandate: https://goo.gl/QLkfZT

Don’t worry if you can’t join us live, simply sign-up and we’ll send you the recordings.

manager

Engaging with multiple influencers – Payers, Patients and Prescribers, equally, has never been so important. Without doing so pharma runs the risk of not getting innovative and costly medication, to the patients.

As we’re dedicating more and more time to the shifting dynamics of stakeholder groups and how we engage with them. It’s essential that we change to a new multi-stakeholder approach, or we run the risk of falling behind. Access your copy here: https://goo.gl/UHZw6W

Our latest whitepaper “Balancing payers, patients and physicians: An integrated multi-stakeholder approach” features key insights from, Actelion, Pfizer, Bayer, Otsuka
Pharmaceuticals, VClinBio and Salesforce and discusses:

• How we can adapt an outdated commercial model to encompass enhanced cross-functional activities, and face the challenges of the industry with a new multi-stakeholder model
• The diminishing influence of the physician in healthcare decision-making, and how companies are increasingly seeing HCP’s as collaborators in patient care
• The changing demands of payers, and how as economic pressures increase their position becomes more influential to patient’s access to medication

Interested? Download your copy here: https://goo.gl/UHZw6W

Any questions, ask Giselle Quartin: gquartin@eyeforpharma.com

Which social media strategies are actually delivering impressive patient, HCP and internal engagement and results? Download the brochure here and discover how 24 pharmaceutical brand speakers from across Europe are adding real strategic value with on-trend social media strategies whilst remaining compliant: https://pharmasocialconference.com/brochure

SAVE £150 before next Thursday! Quote 'PharmeMed' under 'ID Code' to save £150 for The 3rd Annual Pharma Social Media Conference (27th June, London): http://www.etouches.com/pharmasocialconf

1 Day. 24 Pharma Brands Tackle Your Toughest Social Media Challenges: Patient Engagement • Engaging HCPS • Regulatory Context Emerging Trends & Technologies • Measuring Impact • Long-Term Strategy Internal Buy-In • Facebook • Twitter • LinkedIn. See The Full Speaker Line Up Here: https://pharmasocialconference.com

• MSD, Cyril Mandry, Customer Engagement & Social Media Director Europe
• Novartis, Jason Browning, Global Head of Digital Communications & Social Media
• GSK, Alex Saunders, Head Global Digital Communications
• Association of the British Pharmaceutical Industry (ABPI), Aileen Thompson, Executive Director, Communications
• Pfizer, Sarah Holiday, Social Media Strategy Lead (Europe, Japan, South Korea, Australia, New Zealand)
• Merck, Frank Sielaff, Head of Digital Channels, Group Communications
• Roche, Alexander Robbie, Digital Planning Lead
• Gedeon Richter Plc, Zsuzsa Beke, Head of Communications & Government Relation
• Roche, Denisa McKnight, Global Leader Operational Intelligence & Innovation

3 Years At The Front Of The Market & A Stack of Fantastic Testimonials Under Our Belt:

• “High-energy, packed agenda, delivering some really interesting insights.” GSK
• “Great event to network and share inside stories and challenges with like-minded people.” Boehringer Ingelheim

Quote ‘PharmeMed’ under ‘ID Code’ to save £150 when booking online: http://www.etouches.com/pharmasocialconf

Learn how to build and assign NDCs for your Rx or OTC drug product, the first step in electronically registering your product with FDA.

Part of the FDA’s requirement to electronically list drug products (Rx and OTC) includes the assignment of a National Drug Code (NDC). An NDC is a 10 digit number that uniquely identifies a drug product by stringing together three separate code segments. A complete NDC is made up of a labeler code, a product code and package code segment, with dashes between each segment.
This brief guide is intended to give you an overview of NDC structure and best practices for assigning NDCs to your product portfolio.

Download here: http://bit.ly/NationalDrugCode [Currently only available to members located in the United States]

Corden Pharma in Plankstadt Germany trusts in Glatt Technology. In technological partnership with Weiss Pharmatechnik, Glatt provided state of the art pharma process solutions combined with top flexible barrier systems for contained developing service up to OEB 5 Level.

Patient Support Programmes – you’ve probably already noticed; they’re no longer a ‘nice to have’. Nowadays, getting PSPs right can mean the difference between success or failure for your product.

As we dedicate ourselves to find new patient value, we increasingly need our PSPs to be designed as smartly as the medicines they were inspired by. But that’s rarely the case.
Which is why we’re excited to announce a new webinar, demonstrating how a sound understanding of health psychology can ensure the patient’s perspective is baked in from the outset – ensuring adherence to both the program and the medicine is inherent. A mixture of pharma experts, behavioural experts and dedicated Ashfield programme designers will show you the way.

The webinar takes place on Thursday, 26th April and is free to sign up here - https://goo.gl/NAX8zW

(Note that once signed up, you’ll receive a recording even if you were unable to make it on the day.)

Excipient GMP certification is becoming an expectation of pharmaceutical excipient customers. Catch up on this webinar from NSF's expert Jim Morris. Jim describes key elements of the standard, which areas are often cited as weaknesses and strategies for conducting an effective GMP gap assessment of an excipient manufacturer.

Microbubbles/ultrasound contrast agents are small spherical bubbles comprised of three phases, namely innermost gas phase, shell material enclosing the gas phase, and outermost gas or liquid phase. These microbubbles have unique ability to respond to ultrasound; thereby used for ultrasound imaging and research. 

Download Brochure @ https://goo.gl/rBDtMH

Global microbubbles/ultrasound contrast agents market is expected to reach USD 1,584.5 million by 2024, at a CAGR of 25.2% during the forecast period of 2018 to 2024.

A growing demand exists for nutraceuticals, which seem to reside in the grey area between pharmaceuticals and food. The products are thought to provide medical or health benefits "beyond the diet, but before the drugs." A new review published in the British Journal of Clinical Pharmacology looks at the potential of nutraceuticals, stressing the need for a proper definition of nutraceuticals and clear regulations to ensure their safety.

In the review article, a team led by Ettore Novellino, PhD and Antonello Santini, PhD, of the University of Napoli Federico II in Italy, states that nutraceuticals with proven efficacy and health benefits substantiated by clinical data could be used as powerful tools to prevent and treat medical conditions, especially in individuals who may not yet be eligible for conventional pharmaceutical drugs. Therefore, it is of utmost importance to have a proper and unequivocal definition of nutraceuticals, to conduct clinical studies on their safety and efficacy, and to have standardized regulations for their use. In addition, nutraceuticals require a specific classification apart from food supplements and pharmaceuticals.

The authors propose the following definition for nutraceuticals: the phytocomplex of a vegetable or the pool of secondary metabolites from an animal. Both are concentrated and administered in a pharmaceutical form and are capable of providing beneficial health effects, including the prevention and/or treatment of a disease.

Read more: https://www.sciencedaily.com/releases/2018/02/180213084414.htm

“Pharmaceutical Grade Vitamin A Market examines the performance of the Pharmaceutical Grade Vitamin A market 2022. It encloses a complete Research of the Pharmaceutical Grade Vitamin A market state and the competitive landscape ly. This report analyzes the potential of market in the present and the future prospects from various viewpoints in detail. “

Description

Pharmaceutical Grade Vitamin A Market Research Report provides an in-depth analysis of the major Pharmaceutical Grade Vitamin A industry leading players along with the company profiles and strategies adopted by them. This enables the buyer of the report to gain a telescopic view of the competitive landscape and plan the strategies accordingly. A separate section with Pharmaceutical Grade Vitamin A industry key players is included in the report, which provides a comprehensive analysis of price, cost, gross, revenue, product picture, specifications, company profile, and contact information.

The Market Research, besides estimating the Pharmaceutical Grade Vitamin A’ market potential till 2022, analyzes on who can be the market leaders and what partnerships would help them to capture the market share. The Pharmaceutical Grade Vitamin A Industry report gives an overview about the dynamics of the market, by discussing various aspects such as drivers, restraints, Porter’s 5 forces, value chain, customer acceptance and investment scenario

Get a Sample of Pharmaceutical Grade Vitamin A Market Research Report @: https://www.marketreportsworld.com/enquiry/request-sample/10567886

Read more: http://bit.ly/2Et10tz

Never has a data privacy regulation gained so much attention.

From country to country, industry to industry, and role to role the impact of the new EU General Data Protection Regulation (GDPR) will be felt. It affects all who handle health data, and now with its implementation just around the corner (May) it’s more front of mind than ever.

In eyeforpharma’s latest webinar they’re joined by expert panellists; Victoria Perez-Riu, Chief Privacy Officer, AstraZeneca, Nigel Hughes, Scientific Director, Janssen to explore: The Post-GDPR Landscape – Turn Data Requirements into RWD Advantages.

You can sign-up for free here: https://goo.gl/jxT5w8

Key learnings include:
- Determine the business impact of GDPR on future real-world studies – and how to ensure performance doesn’t take a downturn
- Understand how you can continue to make sound investments in data sharing, secondary use and linkage
- Explore the level of stakeholder collaboration required from the ground-up to maintain compliance and move forwards on data quality

Follow this link to make sure you’re signed-up: https://goo.gl/jxT5w8

And, if you can’t make the dates don’t worry, the recordings will be sent to all sign-ups.